May 11, 2017 – Bordeaux
As part of thethird edition of Meet2win (a French oncology business convention entirely dedicated to open innovation, collaborative research, and technology transfer), Professor Stéphane Dedieu and Dr. Albin Jeanne presented the CD 47 project to the Matwin International Board. The project focuses on the development of an innovative molecule that targets a protein overexpressed in tumors, thrombospondin-1, in order to prevent its interaction with the CD47 receptor.
This agent, called TAX2, inhibits tumor progression and metastatic spread in various preclinical models by preventing tumor vascularization while promoting an anti-tumor immune response. In conjunction with the SATT Nord commercialization structure, current developments aim to accelerate the translational potential of TAX2 for use in clinical oncology. Preliminary results tend to prove the immuno-oncological effect of this peptide.
This project is being developed within the MEDyC unit (CNRS UMR 7369) at the University of Reims Champagne-Ardenne (URCA), which focuses on researching extracellular matrix compounds with the aim of identifying new therapeutic targets.